BioSpace1h
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...
Lilly says Mounjaro and Zepbound contributed to big revenue boost
Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker’s stock rose 1.7% in premarket trading after it ...
Manufacturing3h
Diabetes, Obesity Drugs Fuel Eli Lilly Profit in Final Quarter of 2024
Sales of Lilly's top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of ...
dermatologyadvisor23h
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
KYW Radio Philadelphia on MSN3d
Medical Report: FDA approves weight loss drug to treat sleep apnea
As many as 17% of men and 34% of women in the United States suffer from sleep apnea, and the numbers are increasing. KYW ...
HME News6d
ResMed moves to address ‘educational gap’ on PAP devices, GLP-1s
In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...
MassDevice6d
ResMed revenue up 10% in Q2 — but GLP-1 questions remain
ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...